Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: Secondary analyses from the Clinical Trials Network

Journal of Substance Abuse Treatment

Volumn 38, Issue SUPPL. 1, 2010, Pages

  Potter, Jennifer Sharpe ^a,b,c   Chakrabarti, Amit ^b,c   Domier, Catherine P ^d   Hillhouse, Maureen P ^d   Weiss, Roger D ^b,c   Ling, Walter ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Detoxification; Opioid dependence; Pain

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DETOXIFICATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; SECONDARY ANALYSIS; SELF REPORT; SHORT COURSE THERAPY; TREATMENT DURATION; URINALYSIS; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77950218113     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2009.12.007     Document Type: Article

References (22)

1. Amass L., Kamien J.B., Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence 2000, 58:143-152.
2. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. American Journal on Addictions 2004, 13(Suppl 1):S42-S66.
3. Bickel W.K., Amass L., Higgins S.T., Badger G.J., Esch R.A. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting And Clinical Psychology 1997, 65:803-810.
4. Brigham G.S., Amass L., Winhusen T., Harrer J.M., Pelt A. Using buprenorphine short-term taper to facilitate early treatment engagement. Journal of Substance Abuse Treatment 2007, 32:349-356.
5. Caldeiro R.M., Malte C.A., Calsyn D., Baer J.S., Nichol P., Kivlahan D.R., et al. The association of persistent pain with out-patient addiction treatment outcomes and service utilization. Addiction 2008.
6. Diagnostic and Statistical Manual of Mental Disorders. (1994). Washington, DC: American Psychiatric Association.
7. Friedmann P.D., Lemon S.C., Anderson B.J., Stein M.D. Predictors of follow-up health status in the Drug Abuse Treatment Outcome Study (DATOS). Drug and Alcohol Dependence 2003, 69:243-251.
8. Ilgen M.A., Trafton J.A., Humphreys K. Response to methadone maintenance treatment of opiate dependent patients with and without significant pain. Drug and Alcohol Dependence 2006, 82:187-193.
9. Lanser P., Gesell S. Pain management: The fifth vital sign. Healthcare Benchmarks 2001, 8:68-70.
10. Larson M.J., Paasche-Orlow M., Cheng D.M., Lloyd-Travaglini C., Saitz R., Samet J.H. Persistent pain is associated with substance use after detoxification: A prospective cohort analysis. Addiction 2007, 102:752-760.
11. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005, 100:1090-1100.
12. Mark T.L., Kassed C.A., Vandivort-Warren R., Levit K.R., Kranzler H.R. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug and Alcohol Dependence 2009, 99:345-349.
13. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992, 9:199-213.
14. Merrill J.O., Rhodes L.A., Deyo R.A., Marlatt G.A., Bradley K.A. Mutual mistrust in the medical care of drug users: The keys to the "narc" cabinet. Journal of General Internal Medicine 2002, 17:327-333.
15. Modesto-Lowe V., Johnson K., Petry N.M. Pain management in patients with substance abuse: Treatment challenges for pain and addiction specialists. American Journal on Addictions 2007, 16:424-425.
16. Polydorou S., Kleber H.D. Detoxification of opioids. The American Psychiatric Association textbook of substance abuse treatment 2008, American Psychiatric Publishing, Inc, Arlington, VA. 4th ed. M. Galanter, H.D. Kleber (Eds.).
17. Potter J.S., Prather K., Weiss R.D. Physical pain and associated clinical characteristics in treatment-seeking patients in four substance use disorder treatment modalities. The American Journal on Addictions 2008, 17:121-125.
18. Potter J.S., Shiffman S.J., Weiss R.D. Chronic pain severity in opioid-dependent patients. The American Journal of Drug and Alcohol Abuse 2008, 34:101-107.
19. Rosenblum A., Joseph H., Fong C., Kipnis S., Cleland C., Portenoy R.K. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003, 289:2370-2378.
20. Veterans Health Administration National Pain Management Strategy Veterans Health Administration National Pain Management Strategy 1998, Department of Veteran Affairs, Washington, DC.
21. Ware J.E., Kosinski M., Bjorner J.B., Turner-Bowker D.M., Gandek B., Maruish M.E. User's manual for the SF-36v2 Health Survey 2007, QualityMetric Incorporated, Lincoln, RI. 2nd ed.
22. Ziedonis D.M., Amass L., Steinberg M., Woody G., Krejci J., Annon J.J., et al. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA Clinical Trials Network drug and alcohol dependence. Drug and Alcohol Dependence 2009, 99:28-36.